SecBot SecBot
8-K ·Filed Aug 10, 2026

SLN

Silence Therapeutics plc
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001193125-26-341293
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

The compelling Phase 2 data positions divesiran as a potential best-in-class therapy for PV, a large underserved market (~150K US patients). Watch for Phase 3 start in 1H 2027 and potential partnership or licensing interest. The stock is likely to see a strong positive reaction; monitor the conference call for further details on regulatory path and commercial strategy.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$15.43
T+0 close · Aug 10, 2026 · via day close
Latest settled
+28.19%
T+60 · $19.78
Vs SPY
+30.61%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $15.43entry
  2. T+1 · 3mo ago −4.60%α −4.28% · $14.72
  3. T+5 · 3mo ago −7.00%α −6.95% · $14.35
  4. T+20 · 2mo ago −11.28%α −10.36% · $13.69
  5. T+60 · 14d ago +28.19%α +30.61% · $19.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Silence Therapeutics announced positive topline Phase 2 SANRECO trial results for divesiran in polycythemia vera (PV). The primary endpoint was met with a significantly higher proportion of clinical responders (88% vs 19% placebo; p<0.0001), and both Q6W and Q12W dosing showed strong efficacy (93.8% and 81.3% response rates, respectively). The company plans to initiate a Phase 3 trial in 1H 2027, supporting divesiran's potential as a best-in-class siRNA therapy for PV.

Key Facts

  • Primary endpoint met: 88% clinical responders for divesiran vs 19% placebo (p<0.0001), placebo-adjusted response rate 69%.
  • Dose groups: 93.8% response at Q6W and 81.3% at Q12W.
  • Key secondary endpoint: mean phlebotomies reduced to 0.2 (divesiran) vs 2.1 (placebo) during weeks 0-36 (p<0.0001).
  • Safety well-tolerated with no new findings; injection site reactions infrequent and self-limiting.
  • Phase 3 trial evaluating divesiran Q12W vs placebo expected to initiate in first half of 2027.

Financial Impact

No financial data reported; clinical-stage biotech with no revenue. Positive data could significantly increase probability of success and potential partnership value.

revenue (pre-revenue)cash runwayvaluation

Risk Factors

  • Phase 3 trial failure or safety issues could derail development.
  • Regulatory hurdles for siRNA therapy in PV.
  • Competition from existing therapies (JAK inhibitors, interferon) and other pipeline candidates.
  • Need for additional capital to fund Phase 3 and commercialization.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-341293
Document: d12947dex991.htm0001193125-26-341293
Document: d12947dex992.htm0001193125-26-341293
Document: 0001193125-26-341293-index-headers.html0001193125-26-341293
Document: 0001193125-26-341293-index.html0001193125-26-341293
Document: 0001193125-26-341293.txt0001193125-26-341293

Track record

15 reports on SLN

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +7.95% at T+20 after the Aug 10, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
  2. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  3. Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  4. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
  5. Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
  6. Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
  7. Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  8. Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
  9. Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
  10. Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026